Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
2 min synopsisUK scopeSources checked 27 Aug 2026Clinical review pending
!
Escalate
New encephalopathy with hepatic coagulopathy in a patient without established cirrhosis is acute liver failure until proved otherwise. Contact a specialist liver transplant centre immediately and arrange critical-care management; do not wait for coma, a completed aetiology screen or aminotransferase trends before discussing transfer.
Synopsis
Identify the cause and severity of acute hepatitis, recognise transition to acute liver failure, and escalate early for organ support and transplant-centre assessment.
Acute hepatitis is hepatocellular injury developing over days to weeks; causes include viral infection, medicines and toxins, autoimmunity, ischaemia, vascular obstruction, Wilson disease and pregnancy-related syndromes.
Aminotransferase height reflects hepatocyte injury, not remaining liver function. INR, glucose, lactate, pH, mental state, renal function and trajectory identify danger.
Acute liver failure requires acute liver injury with coagulopathy and hepatic encephalopathy in a person without pre-existing cirrhosis; diagnostic and transplant criteria are specialist protocol decisions.
Key red flags
Acute liver failure
New confusion, altered sleep, asterixis, agitation, somnolence or coma with prolonged INR after acute injury signals failing synthetic and detoxification function and mandates transplant-centre contact.
Investigation priorities
01
Liver panel, INR and albuminFirst step
Define injury pattern and assess hepatic synthetic function.
Management branches
TriageAcute hepatitis severity screen
New marked liver-test abnormality, jaundice or a compatible systemic illness.
Assess ABCDE, mental state and asterixis; check bedside glucose, INR, blood gas, lactate, renal function and urine output alongside the liver panel.
Take a time-anchored exposure history covering every medicine, paracetamol-containing product, supplement, toxin, alcohol or drug use, travel, food, sexual, blood and pregnancy risk.
Key medicines
Intravenous acetylcysteineStart and continue according to current TOXBASE, BNF and local weight-based protocol.
Intravenous glucoseTitrate concentrated or maintenance glucose to frequent bedside measurements and critical-care targets.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.